RapidASCVD is a medical calculator designed to estimate 10-year atherosclerotic cardiovascular disease (ASCVD) risk. The app is optimized for clinical efficiency, claiming to provide calculations based on pooled cohort equations within 10-15 seconds.
Overview · Full Intel report in progress
The App DNA
What makes this app unique?
For Busy clinicians requiring rapid cardiovascular risk assessment for patients without prior cardiovascular events.
What does it look like?
Key features
Estimates the probability of first-time coronary heart disease, cerebrovascular disease, and peripheral arterial disease.
Designed for high-speed data entry to facilitate quick clinical workflows.
Utilizes the 2013 ACC/AHA Guideline pooled cohort equations for accuracy.
Calculates risk based on age, cholesterol levels, blood pressure, sex, race, and antihypertensive therapy status.
How much does it cost?
Velocity
Who built it?
ClinCalc
5 apps tracked · Medical
User Sentiment
What do users think recently?
How are ratings & reviews evolving?
Not enough recent reviews to extract reliable themes yet.
Read the full review analysisCompetition
Competitive landscape for RapidASCVD: ASCVD Risk Calc
How's the Medical market?
The rivals identified
By ESC - European Society of Cardiology
Both apps target clinicians performing cardiovascular risk assessments. The ESC app competes by offering a broader suite of calculators, such as and SMART, compared to the singular ASCVD focus of RapidASCVD.
- ESC provides eight distinct risk calculators including and SMART; RapidASCVD focuses exclusively on ASCVD risk.
- ESC is free to download; RapidASCVD requires a 0.99 dollar purchase.
- ESC integrates U-Prevent webtool connectivity for advanced calculators; RapidASCVD operates as a standalone tool.
Unlock the head-to-head verdict: where this rival wins, and where it loses.
Access the full report for freeThe Analyst's Read
Key takeaways for RapidASCVD: ASCVD Risk Calc
Where is it heading?
Bottom line
RapidASCVD is a specialized tool marketed to clinicians for performing rapid, guideline-based cardiovascular risk assessments.
Report last updated